Basic Information
Rixubis
Regulatory Information
EMEA/H/C/003771
Authorised
December 19, 2014
12
November 27, 2024
Company Information
Austria
Industriestrasse 67 1221 Vienna
Baxalta Innovations GmbH
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Overview Summary
This is a summary of the European public assessment report (EPAR) for Rixubis. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rixubis. For practical information about using Rixubis, patients should read the package leaflet or contact their doctor or pharmacist.